marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-07-2024
BioNano Genomics Balance Sheet 2011-2024 | BNGO
Annual Balance Sheet BioNano Genomics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-12.2 M | 788 K | -19.5 M | -2.04 M | 2.77 M | -7.49 M | 5.71 M | 1.38 M | - | - | - | - | - |
Long Term Debt |
3.58 M | 3.62 M | 3.64 M | 16.3 M | - | 9.03 M | - | 6.05 M | - | - | - | - | - |
Long Term Debt Current |
2.16 M | 2.26 M | 1.47 M | - | 20.1 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 16.4 M | 227 K | 10.1 M | 43.7 M | 32.7 M | - | - | - | - | - |
Total Current Liabilities |
100 M | 35.9 M | 21.8 M | 8.94 M | 26.4 M | 4.52 M | - | - | - | - | - | - | - |
Total Liabilities |
118 M | 58.1 M | 40 M | 25.4 M | 26.6 M | 14.7 M | 60.4 M | 42 M | - | - | - | - | - |
Deferred Revenue |
783 K | 871 K | 684 K | 416 K | 357 K | 271 K | 212 K | 447 K | - | - | - | - | - |
Retained Earnings |
-581 M | -349 M | -216 M | -144 M | -103 M | -72.8 M | -54.3 M | -30.9 M | - | - | - | - | - |
Total Assets |
214 M | 308 M | 377 M | 60.4 M | 30.2 M | 24.8 M | 10.1 M | 14.8 M | - | - | - | - | - |
Cash and Cash Equivalents |
17.9 M | 5.09 M | 24.6 M | 38.4 M | 17.3 M | 16.5 M | - | - | - | - | - | - | - |
Book Value |
96.2 M | 249 M | 337 M | 35.1 M | 3.61 M | 10.1 M | -50.2 M | -27.3 M | - | - | - | - | - |
Total Shareholders Equity |
96.2 M | 249 M | 337 M | 35.1 M | 3.61 M | 10.1 M | -50.2 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet BioNano Genomics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.56 M | 3.58 M | 3.58 M | 3.6 M | 3.6 M | 3.61 M | 3.62 M | 3.63 M | - | 3.64 M | 3.64 M | - | - | 14.9 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | - | - | - | 18.4 M | 9.03 M | 9.03 M | 9.03 M | 9.03 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
49 M | 75.2 M | 118 M | 62.9 M | 56.6 M | 60.7 M | 58.1 M | 42 M | - | 37 M | 40 M | 18.1 M | 10.9 M | 22.1 M | 25.4 M | 25.4 M | 25.4 M | 25.4 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 14.7 M | 14.7 M | 14.7 M | 14.7 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
1.15 M | 1.04 M | 783 K | 811 K | 978 K | 1.13 M | 871 K | 976 K | - | 1.11 M | 684 K | 411 K | 445 K | 301 K | 416 K | 412 K | 416 K | 416 K | 357 K | 418 K | 358 K | 214 K | 271 K | 336 K | 271 K | 271 K | 212 K | 212 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-629 M | -613 M | -581 M | -537 M | -425 M | -386 M | -349 M | -310 M | - | -246 M | -216 M | -193 M | -172 M | -154 M | -144 M | -144 M | -144 M | -144 M | -103 M | -103 M | -103 M | -103 M | -72.8 M | -72.8 M | -72.8 M | -72.8 M | -54.3 M | -54.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
129 M | 158 M | 214 M | 182 M | 271 M | 292 M | 308 M | 324 M | - | 348 M | 377 M | 360 M | 357 M | 385 M | 60.4 M | 60.5 M | 60.5 M | 60.5 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 24.8 M | 24.8 M | 24.8 M | 24.8 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.4 M | 15.8 M | 17.9 M | 34.6 M | 14.9 M | 4.1 M | 5.09 M | 28.2 M | 27.2 M | 24 M | 24.6 M | 141 M | 333 M | 362 M | 38.4 M | 38.4 M | 38.4 M | 38.4 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 1.02 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
80.3 M | 82.8 M | 96.2 M | 119 M | 215 M | 231 M | 249 M | 282 M | - | 311 M | 337 M | 342 M | 346 M | 363 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -7.22 M | -7.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
80.3 M | 82.8 M | 96.2 M | 119 M | 215 M | 231 M | 249 M | 282 M | 285 M | 311 M | 337 M | 342 M | 346 M | 363 M | 35.1 M | 35.1 M | 35.1 M | 35.1 M | 3.61 M | 3.61 M | 3.61 M | 3.61 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | -50.2 M | -50.2 M | - | - | -27.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency